COVID-19 - Landscape of novel coronavirus candidate vaccine development worldwide Tuesday, January 05, 2021

All
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3

Summary Information on Vaccine Products in Clinical Development

DISCLAIMER: These landscape documents have been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020 pandemic of the novel coronavirus. Inclusion of any particular product or entity in any of these
landscape documents does not constitute, and shall not be deemed or construed as, any approval or endorsement by WHO of such product or entity (or any of its businesses or activities).  While WHO takes reasonable steps to verify the accuracy of the
information presented in these landscape documents, WHO does not make any (and hereby disclaims all) representations and warranties regarding the accuracy, completeness, fitness for a particular purpose (including any of the aforementioned purposes),
1. quality,
- Number of vaccines
safety, efficacy, in clinical
merchantability development
and/or non-infringement 63 landscape documents and/or of any of the products referenced therein.  WHO also disclaims any and all liability or responsibility whatsoever for any death,
of any information provided in these
disability, injury, suffering, loss, damage or other prejudice of any kind that may arise from or in connection with the procurement, distribution or use of any product included in any of these landscape documents.

2. - Number of vaccines in pre-clinical development 172 Vaccines in clinical development 63

Vaccines in pre-clinical development 172

3. - Candidates in clinical phase

Filter All Select phase of development (default is all)

Platform Candidate vaccines (no. and %)

PS Protein subunit 19 30%
VVnr Viral Vector (non-replicating) 10 16%
DNA DNA 8 13%
IV Inactivated Virus 9 14%
RNA RNA 7 11%
VVr Viral Vector (replicating) 4 6%
VLP Virus Like Particle 2 3%
VVr + APC VVr + Antigen Presenting Cell 2 3%
LAV Live Attenuated Virus 1 2%
VVnr + APC VVnr + Antigen Presenting Cell 1 2%
63

4. - Dosage, schedule and route of admistration of candidates in clinical phase 0% 5% 10% 15% 20% 25% 30% 35%

Dosage & schedule Candidate vaccines (no. and %) PS Chart Title

1 dose 11 17% 1 dose 11 VVnr
Day 0 11 2 doses 38
DNA
2 doses 38 60% 3 doses 1
Day 0 + 14 5 other not s 13 IV
Day 0 + 21 15
RNA
Day 0 + 28 18 Day 0 11
3 doses 1 2% Day 0 + 14 5 VVr
Day 0 + 28 + 56 1 Day 0 + 21 15
VLP
TBD / No Data (ND) 13 21% Day 0 + 28 18
63 Day 0 + 28 1 VVr + APC
Route of admininstration other not s 13 LAV
Oral 3 5%
Injectable 52 83% VVnr + APC
SC Sub cutaneous 2 3%
ID Intra dermal 3 5%
IM Intra muscular 47 75%
TBD / No Data (ND) 8 13%
Landscape of candidate vaccines in clinical development Tuesday, January 05, 2021
DISCLAIMER: These landscape documents have been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020 pandemic of the novel coronavirus. Inclusion of any particular product or entity in any of
these landscape documents does not constitute, and shall not be deemed or construed as, any approval or endorsement by WHO of such product or entity (or any of its businesses or activities).  While WHO takes reasonable steps to verify the accuracy of
the information presented in these landscape documents, WHO does not make any (and hereby disclaims all) representations and warranties regarding the accuracy, completeness, fitness for a particular purpose (including any of the aforementioned
purposes),  quality, safety, efficacy, merchantability and/or non-infringement of any information provided in these landscape documents and/or of any of the products referenced therein.  WHO also disclaims any and all liability or responsibility
whatsoever for any death, disability, injury, suffering, loss, damage or other prejudice of any kind that may arise from or in connection with the procurement, distribution or use of any product included in any of these landscape documents.

* New information that has been added this week.

(NCT04510207 **) This Phase 3 trial assesses both the Wuhan and Beijing vaccine in the same study.
Information highlighted in red indicates a change in the development of the vaccine Current status of clinical evaluation (Trial registries and public repo

Vaccine
ID platform Vaccine platform description Type of candidate vaccine Number of Dosing schedule Route of Developers Phase Phase 1 Phase 1/2 Phase 2
doses administration
acronymn

1 IV Inactivated virus SARS-CoV-2 vaccine (inactivated) 2 Day 0 + 14 IM Sinovac Research and Development Co., Ltd Phase 3 NCT04383574

NCT04352608
NCT04551547
Study Report

Sinopharm + China National Biotec Group Co + Wuhan Institute

2 IV Inactivated virus Inactivated SARS-CoV-2 vaccine (Vero cell) 2 Day 0 + 21 IM Phase 3 ChiCTR2000031809
of Biological Products

Interim Report
Sinopharm + China National Biotec Group Co + Beijing Institute
3 IV Inactivated virus Inactivated SARS-CoV-2 vaccine (Vero cell) 2 Day 0 + 21 IM Phase 3 ChiCTR2000032459
of Biological Products
Study Report
4 VVnr Viral vector (Non-replicating) ChAdOx1-S - (AZD1222) (Covishield) 1-2 Day 0 + 28 IM AstraZeneca + University of Oxford Phase 3 PACTR202005681895696 PACTR202006922165132 NCT04686773
2020-001072-15
Interim Report
NCT04568031
Study Report
NCT04444674
NCT04324606
Study Report
Study Report
NCT04684446

Recombinant novel coronavirus vaccine (Adenovirus type 5

5 VVnr Viral vector (Non-replicating) vector) 1 Day 0 IM CanSino Biological Inc./Beijing Institute of Biotechnology Phase 3 ChiCTR2000030906 ChiCTR2000031781

NCT04313127 NCT04398147 NCT04566770

NCT04568811 NCT04341389
NCT04552366
Study Report Study Report
6 VVnr Viral vector (Non-replicating) Gam-COVID-Vac Adeno-based (rAd26-S+rAd5-S) 2 Day 0 + 21 IM Gamaleya Research Institute ; Health Ministry of the Russian Phase 3 NCT04436471
Federation

NCT04437875
NCT04587219
Study Report

7 VVnr Viral vector (Non-replicating) Ad26.COV2.S 1-2 Day 0 or Day 0 +56 IM Janssen Pharmaceutical Phase 3 NCT04509947 NCT04436276 EUCTR2020-002584-63-DE

NCT04535453

SARS-CoV-2 rS/Matrix M1-Adjuvant (Full length

8 PS Protein subunit recombinant SARS CoV-2 glycoprotein nanoparticle vaccine 2 Day 0 + 21 IM Novavax Phase 3 NCT04368988  NCT04533399
adjuvanted with Matrix M)
Study Report PACTR202009726132275
Study Report
9 RNA RNA based vaccine mRNA -1273 2 Day 0 + 28 IM Moderna + National Institute of Allergy and Infectious Diseases
(NIAID) Phase 3 NCT04283461 NCT04405076

Interim Report
Study Report
10 RNA RNA based vaccine BNT162 (3 LNP-mRNAs ) 2 Day 0 + 28 IM BioNTech + Fosun Pharma ; Jiangsu Provincial Center for Phase 2/3
NCT04523571 2020-001038-36 NCT04649021
Disease Prevention and Control + Pfizer
ChiCTR2000034825 NCT04588480
 NCT04380701
Study Report
NCT04537949
 BNT162 (3 LNP-mRNAs ) 2 Day 0 + 28 IM

EUCTR2020-003267-26-DE
Study Report
Day 0 + 28 or Day 0 Anhui Zhifei Longcom Biopharmaceutical + Institute of
11 PS Protein subunit Recombinant SARS-CoV-2 vaccine (CHO Cell) 2-3 + 28 + 56 IM Microbiology, Chinese Academy of Sciences Phase 3 NCT04445194  NCT04550351 NCT04466085

ChiCTR2000035691  Study Report

 NCT04636333
12 RNA RNA based vaccine CVnCoV Vaccine 2 Day 0 + 28 IM CureVac AG Phase 3 NCT04449276  NCT04515147
PER-054-20
13 IV Inactivated virus SARS-CoV-2 vaccine (vero cells) 2 Day 0 + 28 IM Institute of Medical Biology + Chinese Academy of Medical Phase 3 NCT04470609
Sciences

NCT04412538

14 IV Inactivated virus QazCovid-in® - COVID-19 inactivated vaccine 2 Day 0 + 21 IM Research Institute for Biological Safety Problems, Rep of Phase 3 NCT04530357
Kazakhstan
Inovio Pharmaceuticals + International Vaccine Institute +
15 DNA DNA based vaccine INO-4800+electroporation  2 Day 0 + 28 ID Phase 2/3 NCT04336410 NCT04447781 ChiCTR2000040146 
Advaccine (Suzhou) Biopharmaceutical Co., Ltd
ChiCTR2000038152 
16 DNA DNA based vaccine AG0301-COVID19 2 Day 0 + 14 IM AnGes + Takara Bio + Osaka University Phase 2/3 NCT04463472
NCT04527081
jRCT2051200085
17 DNA DNA based vaccine nCov vaccine 3 Day 0 + 28 + 56 ID Cadila Healthcare Ltd. Phase 3 CTRI/2020/07/026352
18 DNA DNA based vaccine GX-19 2 Day 0 + 28 IM Genexine Consortium Phase 1/2 NCT04445389
19 IV Inactivated virus Whole-Virion Inactivated SARS-CoV-2 Vaccine (BBV152) 2 Day 0 + 14 IM Bharat Biotech International Limited Phase 3
NCT04471519

Report
CTRI/2020/07/026300
CTRI/2020/09/027674
20 PS Protein subunit KBP-COVID-19 (RBD-based) 2 Day 0 + 21 IM Kentucky Bioprocessing Inc. Phase 1/2 NCT04473690
21 PS Protein subunit SARS-CoV-2 vaccine formulation 1 with adjuvant 1 (S 2 Day 0 + 21 IM Sanofi Pasteur + GSK Phase 1/2 NCT04537208
protein (baculovirus production)

22 RNA RNA based vaccine ARCT-021  ND ND IM Arcturus Therapeutics Phase 2 NCT04480957 NCT04668339
23 VLP Virus like particle RBD SARS-CoV-2 HBsAg VLP vaccine 2 Day 0 + 28 IM Serum Institute of India + Accelagen Pty Phase 1/2 ACTRN12620000817943
ACTRN12620001308987
24 IV Inactivated virus Inactivated SARS-CoV-2 vaccine (Vero cell) 1,2 or 3 ND IM Shenzhen Kangtai Biological Products Co., Ltd. Phase 2 ChiCTR2000038804 ChiCTR2000039462 

25 VVnr Viral vector (Non-replicating) GRAd-COV2 (Replication defective Simian Adenovirus 1 Day 0 IM ReiThera + Leukocare + Univercells Phase 1 NCT04528641
(GRAd) encoding S)

26 VVnr Viral vector (Non-replicating) VXA-CoV2-1 Ad5 adjuvanted Oral Vaccine platform 2 Day 0 + 28 Oral Vaxart Phase 1 NCT04563702

27 VVnr Viral vector (Non-replicating) MVA-SARS-2-S 2 Day 0 + 28 IM University of Munich (Ludwig-Maximilians) Phase 1 NCT04569383
28 PS Protein subunit SCB-2019 + AS03 or CpG 1018 adjuvant plus Alum adjuvant 2 Day 0 + 21 IM Clover Biopharmaceuticals Inc./GSK/Dynavax Phase 2/3 NCT04405908
(Native like Trimeric subunit Spike Protein vaccine)
Report
29 PS Protein subunit COVID19 vaccine 1 Day 0 IM Vaxine Pty Ltd. + Medytox Phase 1 NCT04453852
Protein subunit MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 2 Day 0 + 28 IM CSL Ltd. + Seqirus + University of Queensland Phase 1 Development has been suspended and the candidate vaccine has been removed from the landscape sum
30 PS Protein subunit MVC-COV1901 (S-2P protein + CpG 1018) 2 Day 0 + 28 IM Medigen Vaccine Biologics + Dynavax + National Institute of Phase 1 NCT04487210
Allergy and Infectious Diseases (NIAID)
31 PS Protein subunit FINLAY-FR anti-SARS-CoV-2 Vaccine (RBD + adjuvant) 2 Day 0 + 28 IM Instituto Finlay de Vacunas Phase 2 RPCEC00000338 RPCEC00000332 RPCEC00000347

RPCEC00000340
32 PS Protein subunit EpiVacCorona (EpiVacCorona vaccine based on peptide 2 Day 0 + 21 IM Federal Budgetary Research Institution State Research Center Phase 1/2 NCT04527575
antigens for the prevention of COVID-19) of Virology and Biotechnology "Vector"

33 PS Protein subunit RBD (baculovirus production expressed in Sf9 cells) 2 Day 0 + 28 IM West China Hospital + Sichuan University Phase 2 ChiCTR2000037518 ChiCTR2000039994
Recombinant SARS-CoV-2 vaccine (Sf9 Cell)

NCT04530656 NCT04640402

34 PS Protein subunit IMP CoVac-1 (SARS-CoV-2 HLA-DR peptides) 1 Day 0 SC University Hospital Tuebingen Phase 1 NCT04546841

35 PS Protein subunit UB-612 (Multitope peptide based S1-RBD-protein based 2 Day 0 + 28 IM COVAXX + United Biomedical Inc Phase 2/3 NCT04545749
vaccine)
36 VVr Viral vector (Replicating) V591-001 - Measles-vector based (TMV-o38) 1-2 Day 0 + 28 IM Merck & Co. + Themis + Sharp & Dohme + Institute Pasteur + Phase 1/2 NCT04497298 CT04498247
Univeristy of Pittsburgh
NCT04569786
37 VVr Viral vector (Replicating) DelNS1-2019-nCoV-RBD-OPT1 (Intranasal flu-based-RBD ) 1 Day 0 IN Jiangsu Provincial Center for Disease Prevention and Control  Phase 2 ChiCTR2000037782 ChiCTR2000039715
38 RNA RNA based vaccine LNP-nCoVsaRNA 2 ND IM Imperial College London Phase 1 ISRCTN17072692
39 RNA RNA based vaccine SARS-CoV-2 mRNA vaccine 2 Day 0 + 14 or IM Shulan (Hangzhou) Hospital + Center for Disease Control and Phase 1 ChiCTR2000034112
Day 0 + 28 Prevention of Guangxi Zhuang Autonomous Region
ChiCTR2000039212 
40 VLP Virus like particle Coronavirus-Like Particle COVID-19 (CoVLP) 2 Day 0 + 21 IM Medicago Inc. Phase 2/3 NCT04450004 NCT04662697
Study Report
 Covid-19/aAPC vaccine. The Covid-19/aAPC vaccine is
prepared by applying lentivirus modification with immune
41 VVr + APC Viral vector (Replicating) + APC modulatory genes and the viral minigenes to the artificial 3 Day 0 + 14 + 28 SC Shenzhen Geno-Immune Medical Institute Phase 1 NCT04299724
antigen presenting cells (aAPCs).

LV-SMENP-DC vaccine. Dendritic cells are modified with

42 VVnr + APC Viral vector (Non-replicating) + lentivirus vectors expressing Covid-19 minigene SMENP 1 Day 0 SC & IV Shenzhen Geno-Immune Medical Institute Phase 1/2 NCT04276896
APC and immune modulatory genes. CTLs are activated by LV-
DC presenting Covid-19 specific antigens.

43 PS Protein subunit AdimrSC-2f (recombinant RBD +/- Aluminium) ND ND ND Adimmune Corporation Phase 1 NCT04522089
44 DNA DNA based vaccine Covigenix VAX-001 2 Day 0 + 14 IM Entos Pharmaceuticals Inc. Phase 1 NCT04591184
45 DNA DNA based vaccine CORVax 2 Day 0 + 14 ID Providence Health & Services Phase 1 NCT04627675
46 RNA RNA based vaccine ChulaCov19 mRNA vaccine 2 Day 0 + 21 IM Chulalongkorn University Phase 1 NCT04566276
47 DNA DNA based vaccine bacTRL-Spike 1 Day 0 Oral Symvivo Corporation Phase 1 NCT04334980
48 VVnr Viral vector (Non-replicating) hAd5-S-Fusion+N-ETSD vaccine 1 Day 0 Oral ImmunityBio, Inc. Phase 1 NCT04591717
49 VVnr Viral vector (Non-replicating) COH04S1 (MVA-SARS-2-S) 1-2 Day 0 + 28 IM City of Hope Medical Center + National Cancer Institute Phase 1 NCT04639466
Pre-clinical result
50 VVr Viral vector (Replicating) rVSV-SARS-CoV-2-S Vaccine  1 Day 0 IM Israel Institute for Biological Research Phase 1/2 NCT04608305
51 VVr + APC Viral vector (Replicating) + APC Dendritic cell vaccine AV-COVID-19. A vaccine consisting of 1 Day 0 IM Aivita Biomedical, Inc. Phase 1/2 NCT04690387 NCT04386252
autologous dendritic cells loaded with antigens from SARS- National Institute of Health Research and Development,
CoV-2, with or without GM-CSF Ministry of Health Republic of Indonesia

NCT04685603

52 LAV Live attenuated virus COVI-VAC 1-2 Day 0 or IN Codagenix/Serum Institute of India Phase 1 NCT04619628
Day 0 + 28
Day 0 + 14 + 28 or
53 PS Protein subunit CIGB-669 (RBD+AgnHB) 3 Day 0 +28 + 56 IN Center for Genetic Engineering and Biotechnology (CIGB) Phase 1/2 RPCEC00000345

54 PS Protein subunit CIGB-66 (RBD+aluminium hydroxide)   3 Day 0 + 14 + 28 or IM Center for Genetic Engineering and Biotechnology (CIGB) Phase 1/2 RPCEC00000346
Day 0 +28 + 56
RPCEC00000306
55 IV Inactivated Virus VLA2001 2 Day 0 + 21 IM Valneva, National Institute for Health Research, United Phase 1/2 NCT04671017
Kingdom
56 PS Protein subunit BECOV2 2 Day 0 + 28 IM Biological ELimited Phase 1/2 CTRI/2020/11/029032
57 VVr Viral vector (Replicating) AdCLD-CoV19 IM Cellid Co., Ltd. Phase 1/2 NCT04666012
DNA DNA based vaccine GLS-5310 2 Day 0 + 56 or ID GeneOne Life Science, Inc. Phase 1/2 NCT04673149
58 Day 0 + 84
59 PS Protein subunit Recombinant Sars-CoV-2 Spike protein, Aluminum 2 Day 0 + 21 IM Nanogen Pharmaceutical Biotechnology* Phase 1/2 NCT04683484
adjuvanted
60 PS Protein subunit Recombinant protein vaccine S-268019 (using Baculovirus 2 Day 0 + 21 IM Shionogi* Phase 1/2 jRCT2051200092
expression vector system)

61 VVnr Viral vector (Non-replicating) 1-2 Day 0 IN Altimmune, Inc.* Phase 1 NCT04679909
AdCOVID, Adenovirus-based platform expresses the
receptor-binding domain (RBD) of the Sars-Cov-2 spike
protein
62 PS Protein subunit SARS-CoV-2-RBD-Fc fusion protein SC or IM University Medical Center Groningen + Akston Biosciences Inc.* Phase 1/2 NCT04681092
63 IV Inactivated Virus ERUCOV-VAC, inactivated virus 2 Day 0 + 21 IM Erciyes University* Phase 1 NCT04691947
aluation (Trial registries and public reports) Phase 3 endpoints as per protocol

Number of virologically Efficacy compared to placebo Efficacy against severe and Efficacy for the prevention of Efficacy of vaccine against Efficacy of vaccine against Assess humoral
confirmed (PCR or NAAT Safety and immunogenicity of
Phase 2/3 Phase 3 positive) symptomatic cases of for the prevention of SARS- non-severe COVID-19: hospital COVID-19-related Emergency severe and non-severe COVID- severe and non-severe COVID- Efficacy: seronversion rates immunogenicity : antibody a booster dose
COVID-19 CoV-2 infection admissions Department visits 19 19: number of deaths quantification

NCT04456595
X X X X X X
Study Report
NCT04508075 X X X X X X X
 NCT04582344 X X X X X X X X
NCT04617483 X X X
NCT04651790 X X X X X X X X

ChiCTR2000034780 X X X X X

ChiCTR2000039000 X X X X X X X
NCT04510207 ** X X X X
NCT04612972 X X X X X X

NCT04560881 X X X X X X

NCT04510207** X X X X X X X
NCT04400838 ISRCTN89951424 X X X X X X
EUCTR2020-001228-32-GB NCT04516746 X X X X X X
NCT04540393 Suspended (Study has been suspended due to the occurrence of SUSAR at University of Oxford sponsored Phase2/3 study. Study will continue to be on hold until Russian MOH approval is received.)
NCT04536051 X X X X X X
EUCTR2020-005226-28-DE

CTRI/2020/08/027170

NCT04526990 X X X X X

NCT04540419 X X X X X X X

NCT04530396 X X X X X

NCT04564716 X X X X X
NCT04642339 X X X X X
NCT04640233 NCT04656613

NCT04505722 X X X X X X X

NCT04614948 X X X X X X

EUCTR2020-003643-29-DE X X X X X X

EUCTR2020-003643-29-BE X X X X X X

NCT04611802 X X X X X X

EUCTR2020-004123-16-GB X X X X X
 NCT04583995 X X X X X X

NCT04649151 NCT04470427 X X X X X X

Study Report*

NCT04368728 X X X X X X

Study Report
Study Report
 ChiCTR2000040153 X X X X X X

NCT04646590 X X X X X X

NCT04652102 NCT04674189 X X X X X X
EUCTR2020-003998-22-DE
NCT04659239 X X X x X

NCT04691908 X X X X X

NCT04642638 X X X X X X X

NCT04655625 X X X X X

CTRI/2020/07/026352 X X X X X

X X X X X X
NCT04641481; CTRI/2020/11/028976

NCT04672395 X X X X X X

date vaccine has been removed from the landscape summary analysis

NCT04683224 X X X X X X

NCT04636697 X X X X X X
Landscape of candidate vaccines in pre-clinical development
DISCLAIMER: These landscape documents have been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020 pandemic of the novel coronavirus. Inclusion of any particular product or entity in any of these landscape documents
does not constitute, and shall not be deemed or construed as, any approval or endorsement by WHO of such product or entity (or any of its businesses or activities).  While WHO takes reasonable steps to verify the accuracy of the information presented in these landscape documents,
WHO does not make any (and hereby disclaims all) representations and warranties regarding the accuracy, completeness, fitness for a particular purpose (including any of the aforementioned purposes),  quality, safety, efficacy, merchantability and/or non-infringement of any
information provided in these landscape documents and/or of any of the products referenced therein.  WHO also disclaims any and all liability or responsibility whatsoever for any death, disability, injury, suffering, loss, damage or other prejudice of any kind that may arise from or in
connection with the procurement, distribution or use of any product included in any of these landscape documents.

* New information that has been added this week.

Vaccine Same platform for non-

ID platform Vaccine platform description Type of candidate vaccine Coronavirus target
acronymn Coronavirus candidates

1 DNA DNA based vaccine DNA, engineered vaccine inserts compatible with multiple delivery systems SARS-CoV-2 and Sarbeco-
CoV
2 DNA DNA based vaccine DNA vaccine SARS-CoV2
3 DNA DNA based vaccine DNA plasmid vaccine RBD&N SARS-CoV2
4 DNA DNA based vaccine DNA with electroporation SARS-CoV2
5 DNA DNA based vaccine DNA with electroporation SARS-CoV2
6 DNA DNA based vaccine DNA SARS-CoV2
7 DNA DNA based vaccine Plasmid DNA, Needle-Free Delivery SARS-CoV2 SARS
8 DNA DNA based vaccine DNA plasmid vaccine S,S1,S2,RBD &N SARS-CoV2
9 DNA DNA based vaccine DNA vaccine SARS-CoV2
10 DNA DNA based vaccine msDNA vaccine SARS-CoV2
11 DNA DNA based vaccine DNA vaccine SARS-CoV2
12 DNA DNA based vaccine DNA plasmids containing S-gene SARS-CoV2
13 DNA DNA based vaccine DNA plasmid vaccine SARS-CoV2
14 DNA DNA based vaccine Plasmid DNA, nanostructured RBD SARS-CoV2
15 DNA DNA based vaccine DNA plasmid  vaccine encoding RBD SARS-CoV2
16 DNA DNA based vaccine DNA Immunostimulatory sequences SARS-CoV2

Egg-based, inactivated, whole chimeric Newcastle Disease Virus (NDV)

17 IV Inactivated virus expressing membrane-anchored pre-fusion-stabilized trimeric SARS-CoV-2 S SARS-CoV2
protein (Hexapro) + CpG 1018

Egg-based, inactivated, whole chimeric Newcastle Disease Virus (NDV)

18 IV Inactivated virus expressing membrane-anchored pre-fusion-stabilized trimeric SARS-CoV-2 S SARS-CoV2
protein (Hexapro) + CpG 1018

Egg-based, inactivated, whole chimeric Newcastle Disease Virus (NDV)

19 IV Inactivated virus expressing membrane-anchored pre-fusion-stabilized trimeric SARS-CoV-2 S SARS-CoV-2
protein (Hexapro) + CpG 1018
20 IV Inactivated virus Inactivated + alum SARS-CoV2 JE, Zika
21 IV Inactivated virus Inactivated SARS-CoV2
23 IV Inactivated virus SARS-CoV2
24 IV Inactivated virus Inactivated + CpG 1018 SARS-CoV2
25 IV Inactivated virus Inactivated + CpG 1018 SARS-CoV2
26 IV Inactivated virus Inactivated whole virus SARS-CoV2
27 IV Inactivated virus Inactivated SARS-CoV2
28 IV Inactivated virus Inactivated + Alum SARS-CoV2
29 IV Inactivated virus Inactivated SARS-CoV2 MMR, IPV
30 IV Inactivated virus Inactivated SARS-CoV2 MMR, IPV
31 LAV Live attenuated virus Codon deoptimized live attenuated vaccines SARS-CoV2

32 LAV Live attenuated virus Codon deoptimized live attenuated vaccines SARS-CoV2
33 LABV Live attenuated bacterial vector Live attenuated bacterial (Pertussis) Vector SARS-CoV2
34 LABV Live attenuated bacterial vector Live attenuated bacterial vector SARS-CoV2
35 VVnr Viral vector (Non-replicating) Sendai virus vector SARS-CoV2
36 VVnr Viral vector (Non-replicating) Adenovirus-based SARS-CoV2
37 VVnr Viral vector (Non-replicating) Adeno-associated virus vector (AAVCOVID) SARS-CoV2
38 VVnr Viral vector (Non-replicating) MVA encoded VLP SARS-CoV2 LASV, EBOV, MARV, HIV
39 VVnr Viral vector (Non-replicating) MVA-S encoded SARS-CoV2 Multiple candidates
40 VVnr Viral vector (Non-replicating) MVA-S SARS-CoV2
42 VVnr Viral vector (Non-replicating) Adeno5-based SARS-CoV2
43 VVnr Viral vector (Non-replicating) Ad5 S (GREVAX™ platform) SARS-CoV2 MERS
44 VVnr Viral vector (Non-replicating) Oral Ad5 S SARS-CoV2 Zika, VZV, HSV-2 and Norovirus
45 VVnr Viral vector (Non-replicating) adenovirus-based + HLA-matched peptides Pan-Corona
46 VVnr Viral vector (Non-replicating) MVA expressing structural proteins SARS-CoV2 Multiple candidates
47 VVnr Viral vector (Non-replicating) Parainfluenza virus 5 (PIV5)-based vaccine expressing the spike protein SARS-CoV2 MERS

48 VVnr Viral vector (Non-replicating) Recombinant deactivated rabies virus containing S1 SARS-CoV2 HeV, NiV, EBOV, LASSA, CCHFV,
MERS
49 VVnr Viral vector (Non-replicating) Influenza A H1N1 vector SARS-CoV2
50 VVnr Viral vector (Non-replicating) Newcastle disease virus expressing S SARS-CoV2
51 VVnr Viral vector (Non-replicating) Lentiviral Vector SARS-CoV2
52 VVnr Viral vector (Non-replicating) Lentiviral Vector SARS-CoV2
53 VVnr Viral vector (Non-replicating) Lentiviral Vector Retro-VLP Particles SARS-CoV2
54 VVnr Viral vector (Non-replicating) Ad 5 vector for intranasal administration SARS-CoV2
VVnr Viral vector (Non-replicating) TBD SARS-CoV2 InfA, CHIKV, LASV, NORV; EBOV,
55 RVF, HBV, VEE
56 PS Protein subunit RBD protein delivered in mannose-conjugated chitosan nanoparticle SARS-CoV2
57 PS Protein subunit Recombinant spike protein with Essai O/W 1849101 adjuvant SARS-CoV2
58 PS Protein subunit Peptides SARS-CoV2

59 PS Protein subunit Recombinant spike protein with Essai O/W 1849101 adjuvant SARS-CoV2

60 PS Protein subunit Recombinant S protein SARS-CoV2

61 PS Protein subunit RBD protein (baculovirus production) + FAR-Squalene adjuvant SARS-CoV2

62 PS Protein subunit Protein Subunit SARS-CoV2

63 PS Protein subunit RBD-protein SARS-CoV2
64 PS Protein subunit Recombinant S protein SARS-CoV2
65 PS Protein subunit Peptide + novel adjuvant SARS-CoV2
66 PS Protein subunit S subunit intranasal liposomal formulation with GLA/3M052 adjs. SARS-CoV2

67 PS Protein subunit S-Protein (Subunit) + Adjuvant, E coli based Expression SARS-CoV2

68 PS Protein subunit Protein Subunit S,N,M&S1 protein SARS-CoV2

69 PS Protein subunit Protein Subunit SARS-CoV2
70 PS Protein subunit RBD protein fused with Fc of IgG + Adj. SARS-CoV2
71 PS Protein subunit Capsid-like Particle SARS-CoV2
72 PS Protein subunit Drosophila S2 insect cell expression system VLPs SARS-CoV2
73 PS Protein subunit Peptide antigens formulated in LNP SARS-CoV2
74 PS Protein subunit S protein SARS-CoV2
75 PS Protein subunit S protein +Adjuvant SARS-CoV2 Influenza

76 PS Protein subunit VLP-recombinant protein + Adjuvant SARS-CoV2

77 PS Protein subunit microneedle arrays S1 subunit SARS-CoV2 MERS

78 PS Protein subunit Peptide SARS-CoV2
79 PS Protein subunit Adjuvanted protein subunit (RBD) SARS-CoV2
Ebola, Marburg, HIV, Zika,
80 PS Protein subunit Peptide SARS-CoV2 Influenza, HPV therapeutic
vaccine, BreastCA vaccine
81 PS Protein subunit S protein SARS-CoV2
82 PS Protein subunit Ii-Key peptide SARS-CoV2 Influenza, HIV, SARS-CoV
83 PS Protein subunit S protein SARS-CoV2 H7N9
84 PS Protein subunit Protein Subunit EPV-CoV-19 SARS-CoV2
85 PS Protein subunit gp-96 backbone SARS-CoV2 NSCLC, HIV, Malaria, Zika
86 PS Protein subunit Subunit vaccine SARS-CoV2
87 PS Protein subunit S1 or RBD protein SARS-CoV2 SARS
88 PS Protein subunit Subunit protein, plant produced SARS-CoV2
89 PS Protein subunit Recombinant protein, nanoparticles (based on S-protein and other epitopes) SARS-CoV2
90 PS Protein subunit COVID-19 XWG-03 truncated S (spike) proteins SARS-CoV2 HPV
91 PS Protein subunit Adjuvanted microsphere peptide SARS-CoV2
92 PS Protein subunit Synthetic Long Peptide Vaccine candidate for S and M proteins SARS-CoV2
93 PS Protein subunit Oral E. coli-based protein expression system of S and N proteins SARS-CoV2
94 PS Protein subunit Nanoparticle vaccine SARS-CoV2
95 PS Protein subunit Plant-based subunit (RBD-Fc + Adjuvant) SARS-CoV2
96 PS Protein subunit OMV-based vaccine SARS-CoV2 Flu A, Plague
97 PS Protein subunit OMV-based vaccine SARS-CoV2
98 PS Protein subunit structurally modified spherical particles of the tobacco mosaic virus (TMV) SARS-CoV2 Rubella, Rotavirus
99 PS Protein subunit Spike-based SARS-CoV2 Hepatitis C
100 PS Protein subunit Recombinant S1-Fc fusion protein SARS-CoV2
101 PS Protein subunit Recombinant protein SARS-CoV2

102 PS Protein subunit Recombinant S protein in IC-BEVS (Viral vector vaccine SARS-CoV2
(based on baculovirus expression system in insect cell line)
103 PS Protein subunit Orally delivered, heat stable subunit SARS-CoV2
104 PS Protein subunit Peptides derived from Spike protein SARS-CoV2
105 PS Protein subunit Protein Subunit SARS-CoV2
106 PS Protein subunit RBD-based SARS-CoV2
107 PS Protein subunit Outer Membrane Vesicle (OMV)-subunit SARS-CoV2
108 PS Protein subunit Spike-based (epitope screening) SARS-CoV2

109 PS Protein subunit Spiked-based SARS-CoV2

110 PS Protein subunit Recombinant spike with adjuvant SARS-CoV2

111 PS Protein subunit Recombinant S protein produced in BEVS SARS-CoV2
112 PS Protein subunit Protein Subunit Nanoformulated SARS-CoV2
113 PS Protein subunit Protein Subunit Adenoviral Carrier SARS-CoV2
114 PS Protein subunit Protein DC-targeted epitopes SARS-CoV2

115 BVr Bacterial vector (Replicating) Oral Salmonella enteritidis (3934Vac) based protein expression system of RBD SARS-CoV2

116 VVr Viral vector (Replicating) YF17D Vector SARS-CoV2

117 VVr Viral vector (Replicating) Measles Vector SARS-CoV2
118 VVr Viral vector (Replicating) Measles Vector SARS-CoV2
119 VVr Viral vector (Replicating) Measles Virus (S, N targets) SARS-CoV2 Zika, H7N9, CHIKV
120 VVr Viral vector (Replicating) Horsepox vector expressing S protein SARS-CoV2 Smallpox, Monkeypox
Live viral vectored vaccine based on attenuated influenza virus backbone
121 VVr Viral vector (Replicating) (intranasal) SARS-CoV2 Influenza

Recombinant vaccine based on Influenza A virus, for the prevention of COVID-19

122 VVr Viral vector (Replicating) (intranasal) SARS-CoV2 Influenza

123 VVr Viral vector (Replicating) Attenuated Influenza expressing an antigenic portion of the Spike protein SARS-CoV2 Influenza
124 VVr Viral vector (Replicating) Influenza vector expressing RBD SARS-CoV2

125 VVr Viral vector (Replicating) Replication-competent VSV chimeric virus technology (VSVΔG) delivering the SARS-CoV2 Ebola, Marburg, Lassa
SARS-CoV-2 Spike (S) glycoprotein.
126 VVr Viral vector (Replicating) Replicating VSV vector-based DC-targeting SARS-CoV2
127 VVr Viral vector (Replicating) VSV-S SARS-CoV2 HIV, MERS
128 VVr Viral vector (Replicating) VSV-S SARS-CoV2
129 VVr Viral vector (Replicating) VSV vector SARS-CoV2
130 VVr Viral vector (Replicating) M2-deficient single replication (M2SR) influenza vector SARS-CoV2 Influenza
131 VVr Viral vector (Replicating) Newcastle disease virus vector (NDV-SARS-CoV-2/Spike) SARS-CoV2
132 VVr Viral vector (Replicating) Avian paramyxovirus vector (APMV) SARS-CoV3

133 VVr Viral vector (Replicating) Intranasal Newcastle disease virus vector (rNDV-FARVET) expressing RBD SARS-CoV3

134 RNA RNA based vaccine saRNA formulated in a NLC SARS-CoV2

135 RNA RNA based vaccine LNP-encapsulated mRNA encoding S SARS-CoV2
136 RNA RNA based vaccine Self-amplifying RNA SARS-CoV2
137 RNA RNA based vaccine mRNA SARS-CoV2
138 RNA RNA based vaccine LNP-mRNA SARS-CoV2
139 RNA RNA based vaccine LNP-mRNA SARS-CoV2
140 RNA RNA based vaccine LNP-encapsulated mRNA cocktail encoding VLP SARS-CoV2
141 RNA RNA based vaccine LNP-encapsulated mRNA encoding RBD SARS-CoV2
142 RNA RNA based vaccine Replicating Defective SARS-CoV-2 derived RNAs SARS-CoV2
143 RNA RNA based vaccine LNP-encapsulated mRNA SARS-CoV2 MERS
144 RNA RNA based vaccine Liposome-encapsulated mRNA SARS-CoV2
145 RNA RNA based vaccine Several mRNA candidates SARS-CoV2
146 RNA RNA based vaccine mRNA SARS-CoV2
147 RNA RNA based vaccine mRNA SARS-CoV2
148 RNA RNA based vaccine mRNA in an intranasal delivery system SARS-CoV2
149 RNA RNA based vaccine mRNA SARS-CoV2
150 RNA RNA based vaccine mRNA SARS-CoV2
151 RNA RNA based vaccine mRNA SARS-CoV2
152 RNA RNA based vaccine mRNA SARS-CoV2
153 RNA RNA based vaccine mRNA SARS-CoV2
154 RNA RNA based vaccine D614G variant LNP-encapsulated mRNA SARS-CoV2
155 RNA RNA based vaccine Encapsulated mRNA SARS-CoV2
Multiple peptides fragments targeting (S, M, N) and (NSPs) SARS-CoV-2 proteins
156 PS Protein subunit to induce T cell responses (CD8) SARS-CoV2

157 VLP Virus like particle VLP SARS-CoV2

158 VLP Virus like particle Virus-like particle-based Dendritic Cell(DC)-targeting vaccine SARS-CoV2
159 VLP Virus like particle VLP SARS-CoV2
160 VLP Virus like particle VLP SARS-CoV2

161 VLP Virus like particle Enveloped Virus-Like Particle (eVLP) SARS-CoV-2, SARS-CoV, & CMV, GBM, Zika
MERS-CoV

162 VLP Virus like particle S protein integrated in HIV VLPs SARS-CoV2

163 VLP Virus like particle VLP + Adjuvant SARS-CoV2

164 VLP Virus like particle Virus-like particles, lentivirus and baculovirus vehicles SARS-CoV2
165 VLP Virus like particle Virus-like particle, based on RBD displayed on virus-like particles SARS-CoV2
166 VLP Virus like particle ADDomerTM multiepitope display SARS-CoV2
167 VLP Virus like particle Unknown SARS-CoV2
168 VLP Virus like particle VLP SARS-CoV1, SARS-CoV2
169 VLP Virus like particle eVLP SARS-CoV2 Malaria
170 VLP Virus like particle VLPs peptides/whole virus SARS-CoV2
171 VLP Virus like particle VLPs produced in BEVS SARS-CoV2
172 VLP Virus like particle Plant derived VLP SARS-CoV2
 Tuesday, January 05, 2021
on of any particular product or entity in any of these landscape documents
erify the accuracy of the information presented in these landscape documents,
uality, safety, efficacy, merchantability and/or non-infringement of any
ffering, loss, damage or other prejudice of any kind that may arise from or in

Developers

DIOSynVax Ltd + University of Cambridge

Ege University
Scancell/University of Nottingham/ Nottingham Trent University
Karolinska Institute / Cobra Biologics (OPENCORONA Project)
Chula Vaccine Research Center
Takis/Applied DNA Sciences/Evvivax
Immunomic Therapeutics, Inc./EpiVax, Inc./PharmaJet
National Research Centre, Egypt
BioNet Asia
Mediphage Bioceuticals/University of Waterloo
Entos Pharmaceuticals
Biosun Pharmed
Globe Biotech Limited, Bangladesh
National institute of Chemistry, Slovenia
Vaccibody, Oslo Research Park, Norway
Inserm

Institute of Vaccines and Medical Biologicals (IVAC; Vietnam) / Dynavax

/ PATH

Government Pharmaceutical Organization (GPO; Thailand) / Dynavax /

PATH

Institute Butantan (Brazil) / Dynavax / PATH

KM Biologics
Selcuk University
Osaka University/ BIKEN/ NIBIOHN
Sinovac/Dynavax
Valneva/Dynavax
National Research Centre, Egypt
Kocak Farma Ilac ve Kimya San. A.S. 
Shifa Pharmed
Milad Pharmaceutics Co.
Zista Kian Azma Co.
Mehmet Ali Aydinlar University / Acıbadem Labmed Health Services
A.S.
Indian Immunologicals Ltd/Griffith University
Institut Pasteur Lille
ALtraBio, TheRex
ID Pharma
Ankara University
Massachusetts Eye and Ear/Massachusetts General Hospital/AveXis
GeoVax/BravoVax
DZIF – German Center for Infection Research/IDT Biologika GmbH
IDIBAPS-Hospital Clinic, Spain
Erciyes University
Greffex
Stabilitech Biopharma Ltd
Valo Therapeutics Ltd
Centro Nacional Biotecnología (CNB-CSIC), Spain
University of Georgia/University of Iowa

Bharat Biotech/Thomas Jefferson University

National Research Centre, Egypt

Icahn School of Medicine at Mount Sinai
Theravectys – Institut Pasteur
AIOVA
Sorbonne University
University of Helsinki & University of Eastern Finland
Vaxart

Ohio State University / Kazakh National Agrarian University

Kazakh National Agrarian University
Neo7Logic
Kazakh National Agrarian University, Kazakhstan / National Scientific
Center for Especially Dangerous Infections
Max-Planck-Institute of Colloids and Interfaces
Farmacológicos Veterinarios SAC (FARVET SAC) / Universidad Peruana
Cayetano Heredia (UPCH)
Research Institute for Biological Safety Problems, Rep of Kazakhstan
Mynvax
Izmir Biomedicine and Genome Center
Bogazici University
University of Virginia
Helix Biogen Consult, Ogbomoso & Trinity Immonoefficient Laboratory,
Ogbomoso, Oyo State, Nigeria.
National Research Centre, Egypt
University of San Martin and CONICET, Argentina
Chulalongkorn University/GPO, Thailand
AdaptVac (PREVENT-nCoV consortium)
ExpreS2ion
IMV Inc
WRAIR/USAMRIID
National Institute of Infectious Disease, Japan/Shionogi/UMN Pharma
Osaka University/ BIKEN/ National Institutes of Biomedical Innovation,
Japan
Univ. of Pittsburgh
Vaxil Bio
Biological E Ltd

Flow Pharma Inc

AJ Vaccines
Generex/EpiVax
EpiVax/Univ. of Georgia
EpiVax
Heat Biologics/Univ. Of Miami
FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo
Baylor College of Medicine
iBio/CC-Pharming
Saint-Petersburg scientific research institute of vaccines and serums
Innovax/Xiamen Univ./GSK
VIDO-InterVac, University of Saskatchewan
OncoGen
MIGAL Galilee Research Institute
LakePharma, Inc.
Baiya Phytopharm/ Chula Vaccine Research Center
Quadram Institute Biosciences
BiOMViS Srl/Univ. of Trento
Lomonosov Moscow State University
University of Alberta
AnyGo Technology
Yisheng Biopharma

Vabiotech, Vietnam and University of Bristol, UK

Applied Biotechnology Institute, Inc.

Axon Neuroscience SE
MOGAM Institute for Biomedical Research, GC Pharma
Neovii/Tel Aviv University
Intravacc/Epivax
ImmunoPrecise/LiteVax BV
Nanografi Nano Technology, Middle East Technical University, Ankara
University,
Iran
Tampere University
Vaxinano, CEA, INRAE
CEA, CNRS
LinkinVax, VRI
Farmacológicos Veterinarios SAC (FARVET SAC) / Universidad Peruana
Cayetano Heredia (UPCH)
KU Leuven
Cadila Healthcare Limited
FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo
DZIF – German Center for Infection Research/CanVirex AG
Tonix Pharma/Southern Research

BiOCAD and IEM

FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo

Fundação Oswaldo Cruz and Instituto Buntantan

University of Hong Kong

IAVI/Merck

University of Manitoba
University of Western Ontario
Aurobindo
FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo
UW–Madison/FluGen/Bharat Biotech
Intravacc/ Wageningen Bioveterinary Research/Utrecht Univ.
The Lancaster University, UK
Farmacológicos Veterinarios SAC (FARVET SAC) / Universidad Peruana
Cayetano Heredia (UPCH)
Infectious Disease Research Institute/ Amyris, Inc.
Max-Planck-Institute of Colloids and Interfaces
Gennova
Selcuk University
Translate Bio/Sanofi Pasteur
CanSino Biologics/Precision NanoSystems
Fudan University/ Shanghai JiaoTong University/RNACure Biopharma
Fudan University/ Shanghai JiaoTong University/RNACure Biopharma
Centro Nacional Biotecnología (CNB-CSIC), Spain
University of Tokyo/ Daiichi-Sankyo
BIOCAD
RNAimmune, Inc.
FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo
China CDC/Tongji University/Stermina
eTheRNA
Greenlight Biosciences
IDIBAPS-Hospital Clinic, Spain
Providence Therapeutics
Cell Tech Pharmed
ReNAP Co.
Globe Biotech Ltd
CEA
OSE immunotherapeutics

Max Planck Institute for Dynamics of Complex Technical Systems

University of Manitoba
Bezmialem Vakif University
Middle East Technical University

VBI Vaccines Inc.

IrsiCaixa AIDS Research/IRTA-CReSA/Barcelona Supercomputing

Centre/Grifols
Mahidol University/ The Government Pharmaceutical Organization
(GPO)/Siriraj Hospital
Navarrabiomed, Oncoimmunology group
Saiba GmbH
Imophoron Ltd and Bristol University’s Max Planck Centre
Doherty Institute
OSIVAX
ARTES Biotechnology
Univ. of Sao Paulo
Tampere University
Shiraz University